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AbstrAct
Introduction Although bacteria contribute significantly 
to acute exacerbations of chronic obstructive pulmonary 
disease (AECOPD), the added value of antibiotics remains 
controversial, especially in outpatient settings. Age may 
affect antibiotic effectiveness, but real- world evidence is 
lacking. We aimed to assess the influence of age on the 
effectiveness of doxycycline for AECOPD.
Methods A retrospective cohort study among outpatients 
with the first recorded AECOPD treated with oral 
corticosteroids was conducted using a large pharmacy 
dispensing database. The primary outcome was treatment 
failure within 15–31 days after treatment start. Secondary 
outcome was time to second exacerbation. All analyses 
were stratified by age groups.
results We identified 6300 outpatients with the first 
AECOPD. 2261 (36%) received doxycycline and 4039 (64%) 
did not receive any antibiotic (reference group). Overall, 
there was no difference in treatment failure (adjusted 
OR: 0.97, 95% CI: 0.84 to 1.12) between two groups. 
Similarly, no difference in treatment failure was observed 
in younger groups. However, in patients with advanced age 
(≥75 years), treatment failure was significantly reduced 
by doxycycline compared with reference (16% vs 20%, 
adjusted OR: 0.77, 95% CI: 0.62 to 0.97). Overall, median 
time to second exacerbation was 169 days (95% CI: 158 to 
182 days) in doxycycline group compared with 180 days 
(95% CI: 169 to 191 days) in reference group (adjusted 
HR: 1.06, 95% CI: 0.99 to 1.12). Although in older patients 
there was a trend within 3 months towards longer time 
of next exacerbation by doxycycline, it did not achieve 
statistical significance.
conclusions Our findings showed short- term treatment 
benefit of doxycycline added to oral corticosteroids for 
chronic obstructive pulmonary disease patients with 
advanced age. This value remains unclear for persons 
aged under 75 years in current primary care. Long- term 
preventive benefits of doxycycline for the next exacerbation 
were not observed, irrespective of age.
IntroductIon
Chronic obstructive pulmonary disease 
(COPD) is a chronic, progressive, inflam-
matory disease and a leading cause of death 
worldwide.1 Acute exacerbations of COPD 
(AECOPD) characterised by the sudden 
worsening of respiratory symptoms may accel-
erate the progress of COPD and contribute 
significantly to worsened patients’ health 
status, mortality and medical costs.2 3 As about 
50% of AECOPD are triggered by bacterial 
infections,4 the use of antibiotics has become 
a common component in the therapeutic 
management of AECOPD.5 6
The evidence on the benefits of oral corti-
costeroids for AECOPD is of high quality.6 7 
However, the effects of antibiotics in addition 
to corticosteroids are still uncertain, espe-
cially in an outpatient setting. A Cochrane 
review in 2012 did not show a significant 
reduced risk of treatment failure by antibi-
otics.8 Although treatment guidelines in 2017 
conditionally recommended antibiotics for 
AECOPD among outpatients,6 this recom-
mendation was based on synthesised evidence 
from only two earlier randomised controlled 
trials (RCTs).9 10 In the same year, a new large 
RCT concluded that antibiotics for AECOPD 
in an outpatient setting are not effective.11 
Key messages
 ► What are the real- world effects of doxycycline treat-
ment on acute exacerbations of chronic obstructive 
pulmonary disease (AECOPD) in an outpatient set-
ting and does age make any difference?
 ► There are significant benefits of doxycycline in re-
ducing treatment failure of AECOPD among older 
outpatients. This benefits were not found in those 
aged under 75 years. Long- term preventive benefit 
of doxycycline for next exacerbation was not ob-
served, irrespective of age.
 ► This large cohort study evaluated doxycycline effects 
on AECOPD in both short- term and long- term for 
outpatients based on real- world data and highlights 
the possible influence of age on short- term effects 
of doxycycline.
G
roningen. Protected by copyright.
 o
n




pen Resp Res: first published as 10.1136/bmjresp-2019-000535 on 18 February 2020. Downloaded from 
2 Wang Y, et al. BMJ Open Resp Res 2020;7:e000535. doi:10.1136/bmjresp-2019-000535
Open access
Figure 1 Retrospective cohort study design.
Later in 2018, an updated Cochrane review included 
two more RCTs than in 201211 12 and showed statistically 
significant beneficial effects of antibiotics.13 Of note, 
while most RCTs focused on the short- term effect of anti-
biotics, the long- term effect in outpatient settings also 
remains unclear due to conflicting results.11 14 15
The majority of AECOPD is treated in primary care and 
establishing a bacterial infection diagnosis with sputum 
cultures is not always feasible in routine practice due to 
technical reasons.5 16 Therefore, accurate prescribing of 
antibiotics according to guidelines is still low.17–19 Notably, 
many studies indicate that the susceptibility to infections 
increases with age.20 21 According to a large population- 
based observational study, the protective effect of anti-
biotics against pneumonia is more pronounced in older 
patients.22 23 Thus, we hypothesised that older patients 
may benefit more from empirical antibiotic treatment for 
AECOPD than younger patients.
In addition to prednisone or prednisolone, doxycycline 
is one of the first- choice oral antibiotics for AECOPD if 
antibiotic treatment is indicated.5 16 24 Since only one RCT 
studied doxycycline, we conducted a cohort study to eval-
uate if doxycycline has meaningful value added to oral 
corticosteroids on AECOPD in both the short- term and 
longer- term for outpatients, and examined the potential 
effect modification across age groups.
Methods
study design and data source
We applied a retrospective inception cohort study 
(figure 1) using the University of Groningen’s prescrip-
tion database  IADB. nl that contains over 1.2 million 
dispensings from about 600 000 patients in 60 commu-
nity pharmacies in the Netherlands since 1994.25 26  IADB. 
nl provided complete information including date of 
birth, gender, prescribed drug name, anatomical thera-
peutic chemical (ATC) codes, dispensing date, quantity 
dispensed and dose regimen.27 Over- the- counter (OTC) 
drugs and drugs dispensed during hospitalisation are 
not available in the database. As Dutch patients practi-
cally always register at a single community pharmacy, the 
patient’s drug prescription history is usually complete.28 
Data from January 1994 to December 2015 were used 
for this study, which was conducted and reported 
according to checklists of Strengthening the Reporting 
of Observational Studies in Epidemiology guidelines 
(online supplementary material).
study population
COPD outpatients with first recorded AECOPD were 
included in this study. We selected eligible patients 
according to the following inclusion criteria: (1) pres-
ence of COPD identified based on at least two COPD- 
related drug prescriptions (online supplementary table 
S1) within 1 year before index date.5 24 The date of first 
recorded AECOPD during the study period was set as 
index date. (2) The experience of the first recorded 
AECOPD, which was defined by the prescription of high 
dose prednisone (ATC- code H02AB07) or prednisolone 
(H02AB06) short courses (a daily dose of 40 mg for 5 days 
or a daily dose of 30 mg for 7 days with maximum exten-
sion of 14 days) according to treatment guidelines.14 24 29 
(3) Registration in the  IADB. nl for at least 2 years before 
and 1 year after the index date. (4) Receipt of doxycy-
cline or either received any antibiotics 3 days before till 
7 days after the index date. Furthermore, we excluded 
patients who met the following exclusion criteria: (1) 
Receipt of another antibiotic treatment than doxycy-
cline 3 days before till 7 days after the index date. (2) 
Age under 55 years, to reduce the chance of including 
possible asthma patients.30 31 Age was calculated using 
the difference between index date and birth date. (3) 
Presence of potential immunocompromised diseases, 
which were defined by the prescription of antiviral drugs 
for HIV infection, immunosuppressant drugs or anti-
neoplastic agents within 1 year before index date and 
1 month after index date.
exposure and outcomes
Among patients with a first identified AECOPD, during 
their treatment period of oral prednisone or predniso-
lone (3 days before till 7 days after the index date), those 
who were also prescribed doxycycline and no other antibi-
otics were classified as treatment exposure group. Those 
who did not receive doxycycline (or any other antibiotic) 
were classified as reference group. The primary outcome 
was treatment failure defined as a new prescription of 
prednisone or prednisolone or an antibiotic treatment 
within a period of 15–31 days after index date according 
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Figure 2 Flow chart of participation selection. COPD, 
chronic obstructive pulmonary disease.
to Dutch NHG (Nederlands Huisartsen Genootschap) 
guidelines for COPD management. Secondary outcome 
was time to the second exacerbation within a follow- up 
period of 12 months. As the first exacerbation may last 
for a longer time, and to avoid counting it as second 
exacerbation, we limited the minimum time from first 
exacerbation to second one to 21 days.32 A few patients 
could be included in the treatment failure outcome and 
the second exacerbation outcome if the drugs appeared 
within 21 and 31 days after index date.
covariates
The following covariates were included as potential 
confounders: age; gender; frequently used maintenance 
drugs for COPD treatment within 365 days before index 
date including SABA, SAMA (short- acting muscarinic 
antagonist), LABA (ong- acting β agonist), LAMA (long- 
acting muscarinic antagonist), SABA/SAMA, LABA/
LAMA, LABA/ICS (inhaled corticosteroid) and theo-
phylline. Comorbidities in COPD patients were defined 
on the basis of at least two prescriptions of related drugs 
within 365 days prior to index date: diabetes (A10), heart 
failure (C01AA05 or C03C), ischaemic heart disease 
(C01DA), other cardiovascular disease (C02 or C03 or 
C07 or C08 or C09, but not for C01AA05, C03C and 
C01DA), dyslipidaemia (C10), osteoporosis (M05B), 
anxiety (N05B, N05C), dementia (N06D), depression 
(N06A), rheumatic arthritis (M01 or M02) and hypothy-
roid disease (H03).30
statistical methods
The differences in distribution of baseline characteris-
tics of COPD outpatients between two exposure groups 
were compared using t- test and χ2 test for continuous 
and categorical variables, respectively. We applied logistic 
regression to estimate the OR with 95% CI for treatment 
failure and adjusted for possible covariates. The time 
to second exacerbation was compared by Kaplan- Meier 
survival analysis. Cox proportional hazards regression was 
applied to estimate the HR and 95% CI for risk of second 
exacerbation. For all tests, p- values were two- sided. A 
p- value<0.05 was considered statistically significant. All 
analyses were performed using IBM SPSS statistics V.22.
sensitivity analysis
To further assess the robustness of our results, we 
performed several sensitivity analyses. Treatment failure 
was defined by the use of prednisone, prednisolone or 
antibiotics according to Dutch guidelines.24 However, 
considering that not all antibiotics are used for acute 
exacerbations, we narrowed the outcome definition by 
including only frequently prescribed antibiotics among 
COPD patients in Netherlands (online supplementary 
table S2) based on frequencies in the IADB database and 
previous published paper.14 27 In addition, we further 
narrowed the definition of treatment failure by including 
prednisone or prednisolone only to see if there is any 
difference with definition by including antibiotics only. 
Third, considering the COPD treatment may change 
during the long period of study time, we did a sensi-
tivity analysis by limiting our study period to the last 10 
years and compared the result with those from previous 
decade.
Patient and public involvement
Patients were involved in the study indirectly, due to the 
nature of the study, written consent was not required. 
IADB. nl data are collected in accordance with the 
national and European guidelines on privacy require-
ments for handling human data.
results
study participants
In total, 8889 COPD patients with a first recorded 
AECOPD were identified, all received prednisone or 
prednisolone. Of those, we excluded 2589 patients who 
were prescribed another antibiotic than doxycycline, 
that is, our exposure of interest. Of the remaining 6300 
patients, 2261 patients who received doxycycline were 
included as treatment group, and the remaining 4039 
patients who did not receive any antibiotic were included 
as reference group (figure 2).The baseline characteristics 
of both comparison groups are summarised in table 1. 
The two groups were balanced for most characteristics. 
However, the mean age in the doxycycline group was 
slightly higher than the reference group. A little higher 
prevalence of LABA/ICS and doxycycline prescriptions 
and lower prevalence of prescriptions of SABA were seen 
in the doxycycline group compared with reference.
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  Male 1085 (48.0) 1999 (49.5) 0.252
  Female 1176 (52.0) 2040 (50.5)
Age, years, no. (%)
  Mean age (SD) 71.08 (9.6) 70.30 (9.4) 0.002*
  55–64 667 (29.5) 1285 (31.8) 0.018†
  65–74 733 (32.4) 1357 (33.6)
  ≥75 861 (38.1) 1397 (34.6)
Year of index date (%)
  1996–2004 893 (39.5) 1676 (41.5) 0.121
  2005–2015 1368 (60.5) 2363 (58.5)
Prescriber
  GP 2147 (95.0) 3424 (84.8) <0.001
  Specialist 114 (5.0) 615 (15.2)
Maintenance medicines, no. (%)
  SABA 775 (34.3) 1579 (39.1) <0.001
  LABA 494 (21.8) 847 (21.0) 0.414
  SAMA 689 (30.5) 1216 (30.1) 0.761
  LAMA 555 (24.5) 1020 (25.3) 0.534
  SABA/SAMA 80 (3.5) 173 (4.3) 0.149
  LABA/LAMA 0 (0) 1 (0) 0.454
  LABA/ICS 1093 (48.3) 1846 (45.7) 0.044
  Theophylline 124 (5.5) 159 (3.9) 0.004
Comorbidity, no. (%)
  Diabetes mellitus 301 (13.3) 504 (12.5) 0.341
  Disorders of lipid metabolism 629 (27.8) 1093 (27.1) 0.517
  Heart failure 363 (16.1) 676 (16.7) 0.484
  Ischaemic heart disease 206 (9.1) 336 (8.3) 0.282
  Other cardiovascular disorders 843 (37.3) 1493 (37.0) 0.801
  Thyroid disease 115 (5.1) 192 (4.8) 0.556
  Rheumatic arthritis 355 (15.7) 660 (16.3) 0.508
  Osteoporosis 117 (5.2) 232 (5.7) 0.343
  Anxiety 392 (17.3) 649 (16.1) 0.193
  Depression 274 (12.1) 438 (10.8) 0.125
  Dementias 9 (0.4) 10 (0.2) 0.296
*Student’s t- test.
†Pearson χ2 test;.
COPD, chronic obstructive pulmonary disease; GP, general practitioner; ICS, inhaled corticosteroid; LABA, long- acting β agonist; LABA/ICS, 
long- acting β agonist/inhaled corticosteroid; LABA/LAMA, long- acting β agonist/long- acting muscarinic antagonist combinations; LAMA, 
long- acting muscarinic antagonist; SABA, short- acting β agonist; SABA/SAMA, short- acting β agonist/short- acting muscarinic antagonist 
combinations; SAMA, short- acting muscarinic antagonist.
Primary outcome
Between 15 and 31 days after the first exacerbation, 354 
(15.7 %) patients in the doxycycline group versus 640 
(15.8 %) patients in the reference group had treatment 
failure (crude OR: 0.99 (95% CI: 0.89 to 1.14), table 2). 
After adjustment for potential confounders, there still 
was no statistical difference between the two groups 
regarding the rate of treatment failure, the adjusted OR 
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Figure 3 Kaplan- Meier curves showing the proportion of patients free of second exacerbation in COPD outpatients up to 12 
months’ follow- up: (A) all- age group patients (p=0.07); (B) patients aged 55–64 (p=0.252); (C) patients aged 65–74 (p=0.564); 
(D) patients aged ≥75 (p=0.421). COPD, chronic obstructive pulmonary disease.
Table 2 OR for treatment failure of first exacerbation among COPD outpatients in different age groups





Treatment failure (n, %)
Overall 354 (15.7) 640 (15.8) 0.99 (0.86 to 1.14) 0.97 (0.84 to 1.12)
Subgroups
55–65 99 (14.8) 166 (12.9) 1.18 (0.90 to 1.54) 1.17 (0.89 to 1.53)
65–75 116 (15.8) 196 (14.4) 1.11 (0.87 to 1.43) 1.11 (0.86 to 1.42)
≥75 139 (16.1) 278 (19.9) 0.78 (0.62 to 0.97) 0.77 (0.62 to 0.97)
*Adjusted for age, SABA, LABA/ICS, theophylline.
COPD, chronic obstructive pulmonary disease.
(aOR) of treatment failure was 0.97 (95% CI: 0.84 to 
1.12).
In the analysis stratified by age groups, there was no 
significant difference in the rate of treatment failure 
between the two treatments for age groups below 75 years 
old. However, for COPD outpatients aged 75 years and 
older, less patients in the doxycycline group experienced 
treatment failure than in the reference group (16.1% vs 
19.9%, OR: 0.78 (95% CI: 0.62 to 0.97)). After adjust-
ments for possible confounders, the value of OR did not 
change much, and results were compatible with a 23% 
relative risk reduction of treatment failure observed by 
doxycycline treatment compared with reference group 
(aOR: 0.77 (95% CI: 0.62 to 0.97)).
secondary outcome
After a follow- up of 12 months, 71.4% and 67.9% COPD 
outpatients experienced the next exacerbation in doxy-
cycline and reference groups, respectively. The median 
time to next exacerbation was 169 days (95% CI: 156 to 
182) in the doxycycline group compared with 180 days 
(95% CI: 169 to 191) in the reference group (p=0.07, 
figure 3). However, if we included only those patients who 
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experienced a second exacerbation within 12 months 
follow- up, the median time was longer in the doxycycline 
group than in the reference group, though it was not 
statistically significant (97 days (95% CI: 91 to 103) versus 
91 days (95% CI: 86 to 96), p=0.128).
When the results were stratified according to different 
age groups, we did not find significant differences, 
although older people (aged 65–74 and ≥75) on doxy-
cycline experienced a lower risk of next exacerbation 
than the reference group at early time points (within 3 
months) of the follow- up (figure 3). However, we found 
that in both treatment groups, the median time to second 
exacerbation was shorter (p<0.01) in older age groups 
compared with younger age groups (online supplemen-
tary table S3 and figure S1).
Overall, around 30%, 50% and 70% patients in both 
treatment groups experienced a new exacerbation in 
the 3, 6 and 12 months follow- up, respectively (online 
supplementary table S4). From the univariate Cox regres-
sion model, the risk for the next exacerbation was similar 
between two treatment groups, the HR (doxycycline vs 
reference) was 1.00 (95% CI: 0.9 to 1.09), 1.03 (95% CI: 
0.96 to 1.11) and 1.07 (95% CI: 1.00 to 1.14) in 3, 6 and 
12 months follow- up. Similar results were observed after 
adjusting for potential confounding factors, the HR was 
0.98 (95% CI: 0.89 to 1.07), 1.02 (95% CI: 0.95 to 1.09) 
and 1.06 (95% CI: 0.99 to 1.12), respectively.
sensitivity analysis
When we further defined the primary outcome of treat-
ment failure including only frequently used antibiotics, 
it showed consistent results in that doxycycline did not 
reduce treatment failure for the overall cohort (aOR: 
0.99 (0.85 to 1.14)), but that doxycycline treatment 
showed benefits in patients 75 years or older with 137 
patients (15.9 %) and 268 patients (19.2 %) that expe-
rienced treatment failure in the doxycycline group and 
the reference group, respectively (aOR: 0.80 (0.63 to 
1.00)) (online supplementary table S5). When we further 
narrow our treatment failure definition to a new prescrip-
tion of prednisone or prednisolone, we also observed 
reduced treatment failure by doxycycline in the older 
age group compared with reference (aOR: 0.72 (0.55 to 
0.95), online supplementary table S6), while no signif-
icant difference was observed between groups for the 
narrow definition of treatment failure by a new prescrip-
tion of antibiotics. When we limit the study period to 
the last decade (2005–2015) and the previous decade 
(1994–2004) separately, the treatment failure was also 
less among patients with advanced age in doxycycline 
group than reference group (aOR: 0.75 (0.55 to 1.01) 




In a real- world population of primary care patients with 
AECOPD of any age, doxycycline did not appreciably 
reduce the failure rate, nor prolong time to next exac-
erbation. However, when stratified by age, we found a 
statistically significant 23% relative reduction in treat-
ment failure by doxycycline for AECOPD in outpatients 
aged 75 years and older. These benefits were not seen in 
younger age groups. In the long- term, we observed that 
the protective effect of doxycycline for the subsequent 
exacerbations was only present in the first 3 months 
among older patients. After that, the protective effect 
wanes over time.
The observed short- term effect regarding reduction 
rate in treatment failure for older patients (≥75 years) is 
compatible with a previous RCT which found that short- 
term treatment non- response rates are significantly lower 
in the doxycycline group compared with placebo (OR: 
0.77, 95% CI (0.63 to 0.94)).11 Our subgroup result is also 
consistent with a recent Cochrane review that showed 
that the current available antibiotics reduce the risk for 
treatment failure between 7 days and 1 month after treat-
ment initiation (OR: 0.72, 95% CI (0.56 to 0.94)).13
The benefit of doxycycline in older patients may be 
primarily due to their increased susceptibility to infec-
tion.20 With increasing age, not only the lung function 
changes, the natural defence mechanisms of the lungs 
also decrease gradually.33 Intercellular communications 
become less effective which could contribute to immune- 
senescence.34 Additionally, mucocilliary clearance is also 
compromised with age.35 All these changes with age 
contribute to the greater possibility of bacterial infection 
and inflammation in elderly.20 Therefore, the elderly 
seem to benefit more from antibiotic treatment than 
younger patients.
The average age of study patients (about 70 years) 
was comparable with previous studies.36 We did not find 
a short- term benefit of doxycycline in the younger age 
group (<75), which may be explained by the fact that the 
overall rate of appropriate antibiotic use in practice is 
rather low.17–19 According to GOLD (Global Initiative for 
Chronic Obstructive Lung Disease), general practitioners 
should only consider antibiotics for patients when signs 
of bacterial infection are present.5 However, in reality, 
guidelines regarding the prescription of antibiotics are 
poorly followed,17 19 on average in only 25% of AECOPD 
antibiotics were prescribed properly according to the 
GOLD criteria.18 For AECOPD with other aetiology like 
viral infection and environmental pollution, antibiotics 
may not have been effective. Of note, a complicating 
factor in the outpatient setting is that sputum cultures 
are not feasible as they take at least 2 days and frequently 
do not give reliable results.5 Identification of bacterial 
exacerbation still relies on clinical assessment rather 
than laboratory biomarkers.37 As infection is the most 
treatable cause of breathlessness, it is not surprising that 
many patients continue to receive antimicrobials in the 
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absence of clinical, pathological or radiological evidence 
of infection.38 Therefore, if the proportion of patients 
who were prescribed doxycycline but in fact should not 
be given antibiotics is large, it will be difficult to find 
significant beneficial effects of doxycycline treatment.
Observed long- term effects from this study for all 
patients independent of age were also consistent with 
the findings of two previous RCTs that antibiotics did 
not prolong time to next exacerbation.11 39 However, two 
observational studies showed different results in that the 
time to next exacerbation was significantly extended if 
the exacerbation was treated with antibiotics.14 15 Simi-
larly, one RCT also showed a prolonged time to next 
exacerbation by antibiotic treatment.9 In this study, the 
prolonged time to next exacerbation by doxycycline was 
only seen in older outpatients within 3 months. Of note, 
as different definitions for subsequent exacerbation and 
different types of antibiotics were used in these studies 
when evaluating the long- term effect of antibiotics, these 
may lead to the inconsistent results.
Besides the effects of ageing on bacterial suscepti-
bility,22 we should also realise that COPD itself is an age- 
related chronic inflammatory disorder. After the lungs 
reach their maximum function around the age of 25 
years, its function progressively declines as a sequence 
of structural and physiological changes to the lung.33 
With ageing, severity and comorbidities of COPD usually 
also increase. These factors could further influence the 
frequency of exacerbations in primary care patients with 
COPD.40 A higher frequency also means a shorter time to 
experience the next exacerbation. In this study, we have 
found that the time to next exacerbation was shorter in 
older than younger patients, and it was consistent in both 
doxycycline and reference groups.
strengths and limitations
This study has several strengths. One strength is that this 
study was based on a large real- life prescription database 
which enabled us to evaluate the effects of doxycycline 
in a large COPD population. Another strength is that 
both short- term and long- term effects of additional doxy-
cycline were evaluated, which may offer more compre-
hensive support for decision- making in clinical practice. 
Additionally, we chose the first recorded exacerbation 
as investigated event for all COPD outpatients, which 
could exclude the influence of historical exacerbation 
frequency as a risk factor on targeted outcomes to a large 
extent. In addition, as oral steroids and antibiotics cannot 
be bought OTC in the Netherlands, the study population 
from the IADB database represents a generalisable popu-
lation for AECOPD outpatients treated with doxycycline.
Limitations to observational studies also need to 
be discussed. First, due to the characteristics of the 
prescription database, there was no diagnostic infor-
mation available. Therefore, the definition of COPD, 
comorbidities and outcomes were defined using related 
drugs as proxies, which may result in potential misclas-
sification bias. Second, although the relevant measured 
baseline characteristics of the two groups were similar in 
this study, other clinical information like lung function, 
GOLD stages (I–IV) of COPD and severity of exacerba-
tions were lacking, which may influence our outcome 
to some extent if these unknown characteristics were 
not balanced between the two study groups. In clinical 
practice, antibiotics may be prescribed to those who in 
fact did not have enough indication of infection due to 
limitation of outpatients setting or to those with more 
severe COPD,5 which may have led to underestimation 
of the efficacy of additional doxycycline treatment in all 
age groups compared with corticosteroids only. Third, 
there were overlap for a few patients within 21 days and 
31 days between the short- term and long- term outcome 
definitions by a new prescription of corticosteroids due 
to lack of clinical information to distinguish and classify 
the outcomes. Finally, although we set the age limitation 
of 55 years older to exclude potential asthma, asthma- 
COPD overlap patients may still existed as we did not 
exclude the patients who use asthma drugs at the stage of 
study design. However, these patients were very few and 
unlikely to influence the overall results based on the fact 
that no patients were prescribed leukotriene receptor 
antagonists and only 11 patients were prescribed cromo-
glycates within 1 year before index date among all the 
AECOPD patients in our study.
Implications for future research and clinical practice
The tendency towards better effects of antibiotics in the 
elderly COPD patients may offer clues for clinicians and 
researchers for more targeted management of AECOPD. 
In particular, decision- making about empirical antibiotic 
therapy for AECOPD should take the age of patients into 
consideration. However, before that, more prospective, 
well- designed studies with more accurate diagnostic infor-
mation are needed to further confirm the finding from this 
study.
Although related guideline and GOLD report about anti-
biotic use for AECOPD were basically based on secondary 
care RCT evidence,5 6 decision- making in daily practice is 
influenced by many factors making AECOPD treatment 
more challenging in outpatient settings.5 Therefore, iden-
tifying high risk populations for infection may improve 
management and clinical decisions about antibiotic use in 
COPD outpatients. The high risk of infection and benefi-
cial effects from antibiotics for AECOPD in elderly outpa-
tients should warrant a personalised approach towards 
antibiotic treatment.
conclusIon
Doxycycline in addition to oral corticosteroid treatment 
was associated with a reduced risk of treatment failure for 
AECOPD in patients 75 years or older, but not in younger 
patients. Long- term effects of doxycycline treatment on 
subsequent exacerbations was not observed, though among 
older persons there was a non- statistically significant bene-
ficial trend within 3 months after doxycycline treatment. 
Clinicians should take the age of patients into consideration 
G
roningen. Protected by copyright.
 o
n




pen Resp Res: first published as 10.1136/bmjresp-2019-000535 on 18 February 2020. Downloaded from 
8 Wang Y, et al. BMJ Open Resp Res 2020;7:e000535. doi:10.1136/bmjresp-2019-000535
Open access
in empirical antibiotic therapy for AECOPD. More real- 
world studies with high quality, preferably prospective clin-
ical data collections, should be recommended to confirm 
the influence of age on effects of antibiotics and to further 
explore which patient groups could benefit most from anti-
biotic treatment for AECOPD.
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